Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
02185 BIOHEART-B
6.120-0.100-1.61%
Closed
01/27 16:08 CCT
High
6.190
Open
6.030
Turnover
993.50K
Low
6.030
Pre Close
6.220
Volume
162.70K
Price Forecast
News
Comment
Shanghai Bio-heart to Conduct Clinical Trials in Japan for Restenosis Treatment
10:35 PM EST, 11/17/2022 (MT Newswires) -- Shanghai Bio-heart Biological Technology (HKG:2185) said Friday that a clinical trial of the company's sirolimus drug-eluting balloon catheter will be conduc
Individual Investors Among Shanghai Bio-heart Biological Technology Co., Ltd.'s (HKG:2185) Largest Stockholders and Were Hit After Last Week's 6.9% Price Drop
A look at the shareholders of Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185) can tell us which group is most powerful. We can see that individual investors own the lion's share in the
We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Easily Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a ne
Interim report of Propranolol-BVR 2022
The Core Trust Purchases Shanghai Bio-heart Shares for $31.2 Million
01:56 AM EDT, 09/15/2022 (MT Newswires) -- The Core Trust purchased a total of 4,200 H shares of Shanghai Bio-heart Biological Technology (HKG:2185) on the open market for a total of HK$245 million ($
With stock up 9.8%, Insiders of Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185) must be wishing they had bought more last year
Insiders who bought Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185) stock in the last 12 months were richly rewarded last week. The company's market value increased by HK$1.5b as a resul
Shanghai Bio-heart Biological Narrows H1 Loss to $17 Million
03:46 AM EDT, 08/08/2022 (MT Newswires) -- Shanghai Bio-heart Biological Technology (HKG:2185) logs a loss of 115.6 million yuan ($17.1 million) in the six months ended June 30 lower than the loss of
Chairman to Boost Shanghai Bio-heart Stake
09:57 PM EDT, 08/07/2022 (MT Newswires) -- Shanghai Bio-heart Biological Technology (HKG:2185) Chairman Philip Li Wang will buy 600,000 more H Shares of the company in the open market in the next six
Propranolol-B: six months ended June 30, 2022 Interim results announcement
What Kind Of Shareholders Own Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185)?
Every investor in Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, w
Company Overview
More
Shanghai Baixinan Biotechnology Co., Ltd. is a leading interventional cardiovascular device company in China. It is located in the Shanghai Zhangjiang Hi-Tech Park Medical Device Industrial Park. It focuses on two treatments, fully degradable stents (BRS) and renal nerve block (RDN), to address the unmet medical needs of Chinese patients with coronary and peripheral artery disease and hypertension.
The company has a leased area of about 6,500 square meters, has a clean workshop of about 40 million square meters and testing laboratories for all projects of related products, has established a quality management system that meets ISO13485/YY0287 standards, gathers professionals in machinery, materials, precision processing, clinical medicine, etc., and has a team of experienced talents in product design, quality control, clinical verification, and market development.
CEO： Li Wang
Market： Hong Kong motherboard
Listing Date： 12/23/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet